Fluvoxamine Alleviates Paclitaxel-induced Neurotoxicity
Overview
Authors
Affiliations
Paclitaxel (Px) is an effective chemotherapeutic agent for the treatment of various cancers. However, it is often associated with neurological side effects, including chemotherapy-associated cognitive impairment (CACI), such as "chemobrain". Previously, we reported that endoplasmic reticulum (ER) stress is involved in Px-induced neurotoxicity, and immunoglobulin heavy chain binding protein (BiP) inducer X (BIX) alleviates Px-induced neurotoxicity. However, BIX has not been used in clinical practice yet. We recently reported that fluvoxamine (Flv) alleviates ER stress via induction of sigma-1 receptor (Sig-1R). The purpose of this study was to investigate whether Flv could alleviate Px-induced neurotoxicity . SK-N-SH cells were pre-treated for 12 h with or without 10 μg/ml Flv followed by treatment with 1 μM Px with or without co-existence of 10 μg/ml Flv for 24 h. To investigate the involvement of Sig-1R in alleviation effect on Px-induced neurotoxicity,1 μM NE100, an antagonist of Sig-1R, was added for 24 h. Neurotoxicity was assessed using the MTS viability assay and ER stress-mediated neurotoxicity was assessed by evaluating the expression of C/EBP homologous protein (CHOP), cleaved caspase 4, and cleaved caspase 3. Pre-treatment with Flv significantly alleviated the induction of CHOP, cleaved caspase 4, and cleaved caspase 3 in SK-N-SH cells. At the same time, pre-treatment with Flv significantly induced Sig-1R in SK-N-SH cells. In addition, viability was significantly higher in Flv-treated cells than in untreated cells, which was reversed by treatment with NE100. Our results suggest that Flv alleviates Px-induced neurotoxicity in part through the induction of Sig-1R. Our findings should contribute to one of the novel approaches for the alleviation of Px-induced neurotoxicity, including chemobrain.
Asci H, Emre Akin S, Ekrem Camas H, Bindal A, Kurtbolat O, Tasan S Iran J Basic Med Sci. 2025; 28(3):323-331.
PMID: 39906615 PMC: 11790192. DOI: 10.22038/ijbms.2024.80608.17444.
Topsakal S, Ozmen O, Ozcan K, Asci H, Imeci O, Sevuk M Basic Clin Pharmacol Toxicol. 2025; 136(3):e70000.
PMID: 39891570 PMC: 11786297. DOI: 10.1111/bcpt.70000.
Davis M Palliat Care Soc Pract. 2024; 18:26323524241266603.
PMID: 39086469 PMC: 11289827. DOI: 10.1177/26323524241266603.
Lin C, Wu H, Weng E, Wu H, Su T, Wang S Mol Neurobiol. 2024; 61(8):5282-5294.
PMID: 38180612 PMC: 11249700. DOI: 10.1007/s12035-023-03885-9.
A narrative review of risk factors and interventions for cancer-related cognitive impairment.
Bai L, Yu E Ann Transl Med. 2021; 9(1):72.
PMID: 33553365 PMC: 7859819. DOI: 10.21037/atm-20-6443.